<SEC-DOCUMENT>0001493152-18-008568.txt : 20180613
<SEC-HEADER>0001493152-18-008568.hdr.sgml : 20180613
<ACCEPTANCE-DATETIME>20180613060630
ACCESSION NUMBER:		0001493152-18-008568
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20180613
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180613
DATE AS OF CHANGE:		20180613

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protagenic Therapeutics, Inc.\new
		CENTRAL INDEX KEY:			0001022899
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				061390025
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51353
		FILM NUMBER:		18895833

	BUSINESS ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
		BUSINESS PHONE:		(212) 994-8200

	MAIL ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Atrinsic, Inc.
		DATE OF NAME CHANGE:	20090630

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NEW MOTION, INC.
		DATE OF NAME CHANGE:	20070504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MPLC, Inc.
		DATE OF NAME CHANGE:	20050608
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION 13 OR 15(d) OF THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
of Report (Date of Earliest Event Reported): <U>June 13, 2018 </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; border-bottom: Black 1.5pt solid; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>PROTAGENIC
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of Company as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-51353</FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06-1390025</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Tims New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">of incorporation)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">File Number)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Identification No.)</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">149
    Fifth Avenue, Suite 500, New York, NY</FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10010</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">212-994-8200</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 45%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Company&rsquo;s
telephone number, including area code) &nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
    name or former address, if changed since last report)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under
any of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
7.01. Regulation FD.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 13, 2018, Protagenic Therapeutics, Inc. (the &ldquo;Company&rdquo;) issued a letter to its stockholders reporting on the
Company&rsquo;s developmental progress toward filing an FDA Investigational New Drug (IND) application for its three targeted
clinical indications. The stockholder letter, as well as the cover page to the Company&rsquo;s annual report, are furnished as
Exhibit 99.1 hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this Form 8-K (including the Exhibit) shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the
Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by referenced in any filing under the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific referenced in such a filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9.01. Financial Statements and Exhibits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="width: 0.2in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder letter and Annual Report cover page issued on June 13, 2018.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROTAGENIC
    THERAPEUTICS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    June 13, 2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Alexander K. Arrow</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander
K. Arrow, MD</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Financial Officer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 66; width: 200"></FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Face of an Epidemic</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<IMG SRC="ex99-1_002.jpg" ALT="" STYLE="height: 441; width: 650"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Source:
Publicly Available Government Records</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deaths
from prescription Opiates and Heroin is the fastest-growing major</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">cause of death in the U.S., and now exceeds 42,000 per year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 24pt"><B>Protagenic
Therapeutics, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 24pt"><B>2017
Annual Report</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_003.jpg" ALT="" STYLE="height: 66; width: 200"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">149
Fifth Ave, Suite 500</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10010</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Protagenic
Therapeutics, Inc. Update</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
13, 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Fellow Shareholders,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our report last year, I am pleased to report that our efficacy studies have produced profoundly positive results in models of
anxiety and depression. In addition, we have demonstrated positive efficacy results in a new therapeutic field: Addiction Therapy.
Our pre-clinical results indicate that PT00114 may represent a new class of drug candidates to allow addicts to get off and stay
off their addictive drugs, including opioids like oxycontin and fentanyl. Remarkably, PT00114 does this by blunting the effects
of stress that lead to addiction, rather than partially providing the high that opioids produce, as Suboxone does. This opens
up a 3<SUP>rd</SUP> clinical indication for PTI. Given the current worldwide epidemic of opioid addiction and its tragic consequences,
the Board is united in our enthusiasm for this timely new development in PT00114&rsquo;s efficacy studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the last year, the company has made progress in three principal areas:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We&rsquo;ve
    achieved independent confirmation of the efficacy of PT00114 in its original intended indications: chronic anxiety (including
    PTSD) and treatment-resistant depression (TRD). This was achieved with studies conducted for us at highly-respected contract
    research organizations (CROs), two in Europe, and two in the United States.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We&rsquo;ve
    expanded our clinical indications from two to three, with the addition of opioid addiction as a therapeutic target.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We&rsquo;ve
    begun discussions with several potential corporate collaborators. The goal of these discussions is to secure an R&amp;D partnership
    with a major pharmaceutical company. Such a partnership should provide working capital and further elevate the perception
    of the company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
announced just a couple days ago, three recent peer-reviewed publications in major scientific journals have confirmed the central
role of TCAP in brain health. TCAP is the naturally-occurring brain peptide upon which PT00114 is based. In March and April 2018,
the ancient, central role of TCAP in the maintenance of brain health is highlighted in publications in <I>Cell</I>, <I>Nature
Communications,</I> and the <I>Journal of Neuro-endocrinology.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the next 12 months we plan to take steps for our stock, currently trading on the OTC:QB platform, to become more actively traded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we are exploring non-dilutive funding opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our current efforts will result in an IND submission to the FDA in the first half of 2019, pending the outcomes
of our two-species GLP toxicology studies. Preliminary toxicology studies in rodents have shown PT00114 to be non-toxic at quite
high doses for five days. Upon a successful IND submission and acceptance by the FDA, we plan to commence Phase I clinical trials
in 2019. In parallel, we continue to augment our intellectual property estate and will strategically add to our IP portfolio over
time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are excited by our progress to date and for the potential of our novel lead compound to change the way important, stress-mediated
behavioral and mood disorders are treated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Garo
H. Armen, Ph.D.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of Protagenic Therapeutics, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
shareholder letter shall not constitute an offer to sell or the solicitation of an offer to buy any securities. This shareholder
letter is being issued pursuant to and in accordance with Rule 135c under the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Protagenic Therapeutics, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protagenic
Therapeutics, Inc. (OTCQB: PTIX) is a pre-clinical biopharmaceutical company endeavoring to develop first-in-class neuro-active
peptides into human therapeutics to treat anxiety, treatment-resistant depression, and other disorders. For more information,
please visit <U>http://www.protagenic.com</U>. (This website contains stale information and does not appear to include XBRL and
SEC filings)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Cautionary
Statement Relating to Forward - Looking Information for the Purpose of &ldquo;Safe Harbor&rdquo; Provisions of the Private Securities
Litigation Reform Act of 1995 </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
letter contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements contained in this letter,
other than statements of historical fact, constitute &ldquo;forward-looking statements.&rdquo; The words &ldquo;expects,&rdquo;
&ldquo;believes,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;estimates,&rdquo; &ldquo;may,&rdquo; &ldquo;could,&rdquo; &ldquo;intends,&rdquo;
&ldquo;potential,&rdquo; &ldquo;possible,&rdquo; &ldquo;might,&rdquo; &ldquo;look forward,&rdquo; and similar expressions are
intended to identify forward-looking statements. The forward-looking statements in this letter do not constitute guarantees of
future performance. Investors are cautioned that statements in this letter which are not strictly historical statements, including,
without limitation, statements regarding the development of the Company&rsquo;s IND-enabling trials, constitute forward-looking
statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results
to differ materially from those anticipated. These risks and uncertainties include, but are not limited to, risks associated with:
market conditions; our capital position; our ability to compete with larger, better financed pre-clinical biopharmaceutical companies;
our anticipated timing for preclinical development, regulatory submissions, commencement and completion of clinical trials and
product approvals; interpretations of current laws and the passages of future laws; our dependence on product candidates, which
are still in an early development stage; our limited operating history; our ability to raise additional capital through the sale
of shares of our common stock; our ability to obtain, maintain and protect intellectual property rights; the risk of litigation
regarding our intellectual property rights or the rights of third parties; our ability to internally develop new inventions and
intellectual property; our reliance on our license agreement with the University of Toronto; our ability to retain key executives;
our lack of a sales and marketing organization and our ability to commercialize products, if we obtain regulatory approval; our
ability to hire and retain skilled personnel; acceptance of our business model by investors; the accuracy of our estimates regarding
expenses and capital requirements; our ability to adequately support growth; and other risks detailed in our filings with the
SEC, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. These forward-looking
statements speak only as of the date made. We assume no obligation or undertaking to update any forward-looking statements to
reflect any changes in expectations with regard thereto or any change in events, conditions or circumstances on which any such
statement is based. You should, however, review additional disclosures we make in our Annual Reports on Form 10-K, Quarterly Reports
on Form 10-Q, and Current Reports on Form 8-K filed with the SEC. </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !, .8# 2(  A$! Q$!_\0
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MGM;K0O$&O^(]3A$FEZ1XFO=/NY].\.>&IYTU^TU&5-8^S1&UM&F]'_X(W?\
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MC.)6I8BIPY0Y(IQ7+*&$G-WY4ES.HXWYMM&TME^7/[1'[(7[!ND_\$+?A/\
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M[5$!W)<ZU\,_&O@;XD:2IY:]T'7V&017^@E"8IFEGC"NC11@,H)68F*W,;\
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MG5GB,U\-<1A%0_>\29DDL3_NUJO"F&BEB$K?[/RS2K]Z+J^9_3A^Q<G[$A\
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M9)9//"6\;R.R5]"?L.WWQ?O_ (":1=_&X^*Y/$L_B#Q='X<F^(=C8Z9X]OO
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M<%[/VE3E;BYIR;ULHH+#?VE46%RNS:2G4]V*?-?1J]VTGOHDM-7M\8_M.?\
M!(C]@+]JKQ=??$'XH_ ;3!X^U::!=;\8> _$OB7X<ZMJC1.JQS:U%X5\0Z+H
M^KWN2K-J6HZ;>:JTF)!*9&7/JG['_P#P3Q_9,_89D\17'[./PUF\(:KXVMM(
ML/%NO:AXK\7>+-4\26&CW4]YI)NKSQ5KU]:J+.[U9S')IUNC.&,2J\@PG1_M
MKGX[/\#M37X 2ZRGC$:OX?DUB/P7+I=MXRE\")J<3>,8/ UWJ"B2T\42Z.LR
M:1<6["]CU#9]D)D"AJO[$/CWP?XX^&.K_P#"*^+?C#XCN_#_ (YUW2/%>E?'
MO4Y-1^*?@CQ*+BW6_P#"6M"5-]M8VLD;75A$)[B,13%DGD+,D/?B/$CB2>.P
M?AWB,UXQJ9)7P\\=AZ6+E*7"U1T8\_LL'>3C*HN6W+[O(W%\KTD>72RWAQ9_
M6J8?*Z4,Y24ZE5I0DU]J<?LRY;-R^%J\6TTTS[<HHHKK/J@HHHH *S]7L(M5
MTK4]+G>:.'4M/O;"9[>4PSI%>6TMO(\$R\Q3*DA,<HYC<*XY%:%(W0_0_P J
MBI3A5IU*51<U.K"=*I'^:G4A.G./_;T*DX_,4HJ491>THRB_247%_A)GDOP<
M^%/AOX)?#7PA\*_![7W_  C?@W3$T?1QJ%P+V\^QPO/,3)<[5RXN+EP"Z@J-
MJ %5R:/QJ^#OA+X]?#+Q-\+/&C7W_",^,8=-BU9]'N?L6I"VM->L]<L7MKLQ
M2FVE%[81%9S%(L3*\FT@''LB '.>U#J,?ICVY_']:Y:6!H4<*LOA32P$:?LX
M4KNZCJN6^]E=VU\NK,9X6A/#1PKB_9Q2CY..S5KWUCIOHCPG7O@=X0\5_$GX
M0?%?5)M6?Q)\&8O&8\&_9[SR[,CXA:1;>'=:?5=,>P8W+RZ;;(D-PLEK):L)
M)69U9I$]SFBW6\D9(!:-UR3@?,A7J0V!TY*MCT/0JJC('0'_  ]_I4I4, #G
M &/PJ:67X;"1:H1M!Z3B];Q<>1JU]N2\=+:,=+#4*$)4Z,>6$U:26C:<>1KR
MM'1=M#XU\)_L=^$/!WQ9UKXL^'/B/\;-'G\3>.+SXB>(/ ]AX]:'X:ZMXDU.
M&&RU![WP;_8ZQRP7<$*1W#-+'(Z#?]H0@,OU]*@GAFC?A6C9<D$\%2N,9YP#
M]T=<8&,U;"*/\*: &X/ QVXSVYZ^M<&!RC)\KI8W"X3!0IT<RQ,\36II>[.4
MW%OFNVU;6R7?N.CAL/AZ<J=&'+!QY7;1I2YE*VKU:D]=-SXFUC]AWX-:GJ&K
MZX)O%VF>*=2^-I_:$TWQ-I_B#9KOAOXA2VEM8WR^'+@PDP>'[FRLUBU/0E62
M*[M9'A#/O4)]C^7]EA2##W!BC\H22,6)*0 !KAHT9O.G+8RD+$F0;(\DA]18
MU7IG_P"OZ].OUIC$Y(R>"1_^O%:4,MR? UZE;#Y?3A*JIQFXZ7<E-/1MVOSO
M75]-MC#X>CA4XT(\L9.\E_-=MN]M&_>EK;KO;0^4KC]D?X(:OX^^)/Q&\5>$
M=,^(/B;XFW6A?VS-\1-*T+Q3!I$7AC1)='LK'P;'?:*+G2;)+>:1+D6\PE>0
M>9%-$80#Z-\%?@]X7^!7PW\-_"OP=>:]J/A?PK;W=IHQ\3ZH^M:G!IFH:A=7
MHM'U)TB%YI=D]T8+&T9=UE81P6Y<QI"E>U;!ZG]/\*8P ( ]/ZFG0RS)\OK2
MQV#RZC2Q==J%2JM)-59)3O+6_P 3>S;>B<4S.&!PT<2\3&/OM2Z);W;U6KUU
M]Z^J5K=?%?'7P3\(?$7QW\(_B/KLFL1Z]\&-<\0Z_P"#UMM0:TMC?>+-.&C:
MHFKVGEO]JA-F!%9PF2/:6*@L#BO9W0")U.065AGK_#@G'.?IS["G!B.A_E4A
M&5R3GC/0>GTKNIX:CAJU3$P34ZFK5^J5[7?=)+;UOUW48KIIS)O1:V:\O(^<
M?V@_V>_"/[0F@^&='\6ZQXK\/)X.\9Z3\1=#U;P9XAE\-:U8>(O#UMJT.EWU
MKJD<<C64UE+JQO(KD1F2"ZB@EC9/+8CMOA=\.Q\+?!NF^$(_%_C_ ,<G3I-2
MD_X2+XD^)9/%'BW4!=7IEVZEK3P0/>16X<)9(T:E8%B0\[L^L*H*C(_SDTUP
M!C'&<]/PKSJ>5Y/A<=6SRAEU..95H-5*RDTY>Z_/E3TLY<M[;69G3PU&&*EB
M5'WYV35W;3:^MG;3I\SPKXZ_ ?P3^T%X,C\&^-UUBULK+5=+\1Z-K'AS5I=#
M\0>'_$>AW'V[1M?T/4X5+Z?J^D7J1WVG7?ER?9KR&&=5#1\\Q\"_V7_!?P3U
MSQ-XNLO$7CSQ]XX\90Z;::]X\^)OBF3Q9XEOM+T==FFZ5!>-#;)#8V<:HJ0K
M I!C#;R!MKZ: &T^V,?RI3QMQZ!OQ_S_ )Y-9?V5DL\4L]>6TO[2JN"E7NW+
MFYHQ3>O*W&]U+EO;16>IE4P&'J8MXIQ_>=7YQ3L][-I-I-Q;2;2:38D\>Z*1
M5P,HXRQ(7E3@D]@.I]LUXQ\*_@IX/^$6I?$[4O#$FJ?:OBU\4->^*/B5=3NO
M-'_"2:^MK]O33HV5#%8B*T7RXAO81KMW97->T;V]?T%-KV*V$H8B4)UH<TH.
M,HN^THM25GY.*^XZ%"*Z=&MEUWZ>;*>IV$&H6%[9SLZ6UY:7-K/)%(894AN(
M7AE:.4<Q2(CL4D_@(#=N/-?@]\)?"_P.^&7@_P"$?@Y]4;PMX*TXZ3HCZI>-
M?ZAY'G7%XWVZ[,<6YOM5W(UJ0H*$0[2P3+>L!B. ?T%(23U-*.&I4\1/%J-Z
MG*^MMDV^ZU:ZJW>Z'RQ]VZ^&W1;73M^!\Z_'O]G3P!^T9X<TG0?'$>L65SH.
MM67BCPMXF\(ZP_A[Q;X3\36KJZ:MX9UN*,O;3H1YLTC)*LFU2T4CK$8=SX-?
M""W^#7AG4/#<'CWXF?$ ZGJYUFYUSXL>+9O&GB2*1[#2M+BL8]8DCMMNF@:3
M&5L I7S))P&Q(=WN2J"HR/\ .337 &,<9ST_"O-AE>387'UL]H9=2AF5:#]I
M73:E+1NS?PZ+2_*W;9F4,-0CBI8E0]^6C]-;7UUM>RNKI.U['C_Q=^&<?Q6\
M)3^%I/&WQ!^'[2WEI>?\)%\,O%#>$O%-DUG+Y@LX=<1)S':WY98IK4Q%9494
M8", C&^!?P&\#_L_Z#J>A>#WU[5+KQ-XCNO%?B?Q-XIU8Z_XL\5^)-3$4-[J
MVNZS,D4E[/'%"A9BBA%#>6"Q;S?>E4,.>Q_PXH*A2N.Y_J*?]E9-/%QSR674
MWF-10BZ[E)R]YQ2M=\MT[:J-VHI/6XXX6C'$RQ%FYM2BM7:*:>UV[?**;6CD
*[(DHHHKVS8__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_002.jpg
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'G LT# 2(  A$! Q$!_\0
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M+ ,7QC(Z9 P,>E:5MI-Q_P )#9ZG/JEDS+;M$L-M;&+S8S@CK(V0#@]*6_\
M7D#T_KS-1-:TJ1(G34[-DF?RXF$ZD.W]T<\GV%.N=5TZSG6"ZU"U@F?[L<LR
MJS?0$YKFO"NEZ=?V5^TUO%(T>K32*PZJROE<$?RZ4GAN"TU#1=:AU=8WDDOI
M1>B1L8P?EYSD #&/TH7_  ?R_P P_K\_\CJ;O4;&P"&\O+>V#G"F:54W'VR>
M:)M0LK>2&.>\MXGG.(5>55,G^Z">>HZ5R5M!?7'C37H5N;.)O*B2-;FV:4F
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME'4JP]0:RX?#.D6[1>7:MLA(:.)IG:)&'0A"VT'WQFDM_N#_ ()@W45AX?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&_QJ6B@"+R$_O2?]_&_QH\A/[TG_ '\;_&I:* (O(3^])_W\;_&CR$_O2?\
M?QO\:EHH B\A/[TG_?QO\:/(3^])_P!_&_QJ6B@"+R$_O2?]_&_QH\A/[TG_
M '\;_&I:* (O(3^])_W\;_&CR$_O2?\ ?QO\:EHH B\A/[TG_?QO\:/(3^])
M_P!_&_QJ6B@"+R$_O2?]_&_QH\A/[TG_ '\;_&I:* (O(3^])_W\;_&CR$_O
M2?\ ?QO\:EHH B\A/[TG_?QO\:/(3^])_P!_&_QJ6B@"+R$_O2?]_&_QH\A/
M[TG_ '\;_&I:* (O(3^])_W\;_&CR$_O2?\ ?QO\:EHH B\A/[TG_?QO\:/(
M3^])_P!_&_QJ6B@"+R$_O2?]_&_QH\A/[TG_ '\;_&I:* (O(3^])_W\;_&C
MR$_O2?\ ?QO\:EHH B\A/[TG_?QO\:/(3^])_P!_&_QJ6B@"+R$_O2?]_&_Q
MH\A/[TG_ '\;_&I:* (O(3^])_W\;_&CR$_O2?\ ?QO\:EHH B\A/[TG_?QO
M\:/(3^])_P!_&_QJ6B@"+R$_O2?]_&_QH\A/[TG_ '\;_&I:* (O(3^])_W\
M;_&CR$_O2?\ ?QO\:EHH B\A/[TG_?QO\:/(3^])_P!_&_QJ6B@"+R$_O2?]
M_&_QH\A/[TG_ '\;_&I:* (O(3^])_W\;_&GI&$S@L<_WF)_G3J* "HE_P"/
MJ3_<7^;5+42_\?4G^XO\VH +;_CUA_W!_*I:BMO^/6'_ '!_*I: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHILC;(V;T!- #J*\R_P"%I7?_ $#(/^_A
MK=\*>,Y_$6J2VDMG'"J0F7<KDDX91C]:UE1G%7:*<6CL****R)"HE_X^I/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !3)O\ 42?[I_E3Z9-_J)/]T_RH ^=J
M[7X8_P#(RW/_ %YM_P"AI7%5VOPQ_P"1EN?^O-O_ $-*].M_#9O+8]7HHHKS
M# *B7_CZD_W%_FU2U$O_ !]2?[B_S:@ MO\ CUA_W!_*I:BMO^/6'_<'\JEH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1>4__/Q)^2_X4>4__/Q)^2_X4 2T5%Y3_P#/Q)^2_P"%'E/_ ,_$GY+_ (4
M2T5%Y3_\_$GY+_A1Y3_\_$GY+_A0!+147E/_ ,_$GY+_ (4>4_\ S\2?DO\
MA0!+147E/_S\2?DO^%'E/_S\2?DO^% $M%1>4_\ S\2?DO\ A1Y3_P#/Q)^2
M_P"% $M%1>4__/Q)^2_X4>4__/Q)^2_X4 2T5%Y3_P#/Q)^2_P"%'E/_ ,_$
MGY+_ (4 2T5%Y3_\_$GY+_A1Y3_\_$GY+_A0!+147E/_ ,_$GY+_ (4>4_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ID
MW^HD_P!T_P J?3)O]1)_NG^5 'SM7:_#'_D9;G_KS;_T-*XJNU^&/_(RW/\
MUYM_Z&E>G6_ALWEL>KT445YA@%1+_P ?4G^XO\VJ6HE_X^I/]Q?YM0 6W_'K
M#_N#^52U%;?\>L/^X/Y5+0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,F_
MU$G^Z?Y4^F3?ZB3_ '3_ "H ^=J[7X8_\C+<_P#7FW_H:5Q5=K\,?^1EN?\
MKS;_ -#2O3K?PV;RV/5Z***\PP"HE_X^I/\ <7^;5+42_P#'U)_N+_-J "V_
MX]8?]P?RJ6HK;_CUA_W!_*I: .8\12W!UJSMD^V7$)MY7:UL9S#+D$8<MN7Y
M1G&,]3T-9EC<W6KI964NI7.$TMKDRP2-&SR;MHR1@G;@Y!X)ZBNHO]'2^NXK
MM+JYM+F-&C$MN5R4.,J0RD=0#TS563PK8^1;QVTMS:&&%H-\+C<\;'+*Q8'.
M3SGKGH12Z?UYCZ_UY'.6NJ:E,EAJ=T]XH,5O*70-Y'E;29B^/ES]>>F*Z'0M
M5BN)I8;BYD-_,S2F!@VV(#'R*2-I*@KN /4FKL^D12VMG9QL(K*W9280N=ZJ
M/E7.>F0#[XJM9Z UKJYO#=;X5>62*'R\%&D(+9;/(X..!U[U5]2;:&U4;3*K
M$$/D>B$_TJ2BD,B\]/[LG_?MO\*//3^[)_W[;_"I:* (O/3^[)_W[;_"CST_
MNR?]^V_PJ6B@"+ST_NR?]^V_PH\]/[LG_?MO\*EHH B\]/[LG_?MO\*//3^[
M)_W[;_"I:* (O/3^[)_W[;_"CST_NR?]^V_PJ6B@"+ST_NR?]^V_PH\]/[LG
M_?MO\*EHH B\]/[LG_?MO\*//3^[)_W[;_"I:* (O/3^[)_W[;_"CST_NR?]
M^V_PJ6B@"+ST_NR?]^V_PH\]/[LG_?MO\*EHH B\]/[LG_?MO\*//3^[)_W[
M;_"I:* (O/3^[)_W[;_"CST_NR?]^V_PJ6B@"+ST_NR?]^V_PH\]/[LG_?MO
M\*EHH B\]/[LG_?MO\*//3^[)_W[;_"I:* (O/3^[)_W[;_"CST_NR?]^V_P
MJ6B@"+ST_NR?]^V_PH\]/[LG_?MO\*EHH B\]/[LG_?MO\*//3^[)_W[;_"I
M:* (O/3^[)_W[;_"CST_NR?]^V_PJ6B@"+ST_NR?]^V_PH\]/[LG_?MO\*EH
MH B\]/[LG_?MO\*//3^[)_W[;_"I:* (O/3^[)_W[;_"CST_NR?]^V_PJ6B@
M"+ST_NR?]^V_PH\]/[LG_?MO\*EHH B\]/[LG_?MO\*//3^[)_W[;_"I:* (
MO/3^[)_W[;_"CST_NR?]^V_PJ6B@"+ST_NR?]^V_PH\]/[LG_?MO\*EHH B\
M]/[LG_?MO\*//3^[)_W[;_"I:* (O/3^[)_W[;_"CST_NR?]^V_PJ6B@"+ST
M_NR?]^V_PH\]/[LG_?MO\*EHH B\]/[LG_?MO\*//3^[)_W[;_"I:* (O/3^
M[)_W[;_"CST_NR?]^V_PJ6B@"+ST_NR?]^V_PH\]/[LG_?MO\*EHH B\]/[L
MG_?MO\*//3^[)_W[;_"I:* (O/3^[)_W[;_"CST_NR?]^V_PJ6B@#FO$_BX>
M'/LN+)KCS]_WG,>W;M]5.>M<]_PM7_J#?^37_P!A1\5?^83_ -MO_9*\YKMH
MT82@FT:QBFCWS2M574M+MKTPO&9D#[ K-C\<<U;\]/[LG_?MO\*R_"?_ "*F
MF?\ 7 5LUQR5FT9O<B\]/[LG_?MO\*//3^[)_P!^V_PJ6BD(B\]/[LG_ '[;
M_"CST_NR?]^V_P *EHH B\]/[LG_ '[;_"CST_NR?]^V_P *EHH B\]/[LG_
M '[;_"F33IY$G$GW3_RS;T^E6*9-_J)/]T_RH ^=J[/X:.$\1W!(;_CT;HI/
M\:>E<97:_#'_ )&6Y_Z\V_\ 0TKTZW\-F\MCU+ST_NR?]^V_PIZ2!\X##']Y
M2/YTZBO,, J)?^/J3_<7^;5+42_\?4G^XO\ -J "V_X]8?\ <'\JEJ*V_P"/
M6'_<'\JEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#SGXJ_\ ,)_[;?\ LE><UZ-\5?\ F$_]MO\ V2O.:]&A
M_#1M#8]S\)_\BIIG_7 5LUC>$_\ D5-,_P"N K9K@G\3,GN%%%%2(**** "B
MBB@ IDW^HD_W3_*GTR;_ %$G^Z?Y4 ?.U=K\,?\ D9;G_KS;_P!#2N*KM?AC
M_P C+<_]>;?^AI7IUOX;-Y;'J]%%%>88!42_\?4G^XO\VJ6HE_X^I/\ <7^;
M4 %M_P >L/\ N#^52U%;?\>L/^X/Y5+0 454O]1@T](_,#O+*VV*&,;GD;K@
M#^IX'>JM_KL6GB)7L[J6=XFF:"(*7C1<;BWS8XR!P3GMF@#5HK&7Q-8R74$4
M2S21S"/%PJCRU,@R@.3G)QV!ZC.*T+2^BO6G\E7*0R&(N0-K,.NWUP>/J#0!
M9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHKG)_'.@6UQ+!+=N)(W*,/)<X(.#VIJ+EL
M@M<Z.BL+3_&&BZI?1V5I<L\\F=JF)AG )/)'H#6[0XM;A:P4444@"BBB@ HH
MHH **** /.?BK_S"?^VW_LE><UZ-\5?^83_VV_\ 9*\YKT:'\-&T-CW/PG_R
M*FF?]<!6S6-X3_Y%33/^N K9K@G\3,GN%%%%2(**** "BBB@ IDW^HD_W3_*
MGTR;_42?[I_E0!\[5VOPQ_Y&6Y_Z\V_]#2N*KM?AC_R,MS_UYM_Z&E>G6_AL
MWEL>KT445YA@%1+_ ,?4G^XO\VJ6HE_X^I/]Q?YM0 6W_'K#_N#^52U%;?\
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MM_QZP_[@_E4M16W_ !ZP_P"X/Y5+0 45ROC77%L=.FL8;^.TO)+=Y0YE",%
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M147GI_=D_P"_;?X4>>G]V3_OVW^% $M%1>>G]V3_ +]M_A1YZ?W9/^_;?X4
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M*//3^[)_W[;_  H EHJ+ST_NR?\ ?MO\*//3^[)_W[;_  H EHJ+ST_NR?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M =:_Y#NH?]?,G_H1KWZO =:_Y#NH?]?,G_H1KJPN[-*9J^ _^1TT_P#[:?\
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M .?B3\E_PH\I_P#GXD_)?\*X3(EHJ+RG_P"?B3\E_P */*?_ )^)/R7_  H
MEHJ+RG_Y^)/R7_"CRG_Y^)/R7_"@"6BHO*?_ )^)/R7_  H\I_\ GXD_)?\
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M^Z?Y4WRG_P"?B3\E_P *9-$_D2?OY/NGLOI]* /GNNU^&/\ R,MS_P!>;?\
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M*JS(23"P &1[5[E179'&2C!1L<TL,G+FN1?:8/\ GM'_ -]"C[3!_P ]H_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMG_YZ1_]^S_C1MG_ .>D?_?L_P"-2T4 1;9_^>D?_?L_XT;9_P#GI'_W[/\
MC4M% $6V?_GI'_W[/^-&V?\ YZ1_]^S_ (U+10!%MG_YZ1_]^S_C1MG_ .>D
M?_?L_P"-2T4 1;9_^>D?_?L_XT;9_P#GI'_W[/\ C4M% $6V?_GI'_W[/^-&
MV?\ YZ1_]^S_ (U+10!%MG_YZ1_]^S_C1MG_ .>D?_?L_P"-2T4 1;9_^>D?
M_?L_XT;9_P#GI'_W[/\ C4M% $6V?_GI'_W[/^-&V?\ YZ1_]^S_ (U+10!%
MMG_YZ1_]^S_C1MG_ .>D?_?L_P"-2T4 1;9_^>D?_?L_XT;9_P#GI'_W[/\
MC4M% $6V?_GI'_W[/^-&V?\ YZ1_]^S_ (U+10!%MG_YZ1_]^S_C1MG_ .>D
M?_?L_P"-2T4 1;9_^>D?_?L_XT;9_P#GI'_W[/\ C4M% $6V?_GI'_W[/^-&
MV?\ YZ1_]^S_ (U+10!%MG_YZ1_]^S_C1MG_ .>D?_?L_P"-2T4 1;9_^>D?
M_?L_XT;9_P#GI'_W[/\ C4M% $6V?_GI'_W[/^-&V?\ YZ1_]^S_ (U+10!%
MMG_YZ1_]^S_C1MG_ .>D?_?L_P"-2T4 1;9_^>D?_?L_XT;9_P#GI'_W[/\
MC4M% $6V?_GI'_W[/^-&V?\ YZ1_]^S_ (U+10!%MG_YZ1_]^S_C1MG_ .>D
M?_?L_P"-2T4 1;9_^>D?_?L_XT;9_P#GI'_W[/\ C4M% $6V?_GI'_W[/^-&
MV?\ YZ1_]^S_ (U+10!%MG_YZ1_]^S_C1MG_ .>D?_?L_P"-2T4 1;9_^>D?
M_?L_XT;9_P#GI'_W[/\ C4M% $6V?_GI'_W[/^-&V?\ YZ1_]^S_ (U+10!%
MMG_YZ1_]^S_C1MG_ .>D?_?L_P"-2T4 1;9_^>D?_?L_XT;9_P#GI'_W[/\
MC4M% $6V?_GI'_W[/^-&V?\ YZ1_]^S_ (U+10!%MG_YZ1_]^S_C1MG_ .>D
M?_?L_P"-2T4 1;9_^>D?_?L_XT;9_P#GI'_W[/\ C4M% $6V?_GI'_W[/^-/
M02#.]E;TVKC^IIU% !42_P#'U)_N+_-JEJ)?^/J3_<7^;4 %M_QZP_[@_E4M
M16W_ !ZP_P"X/Y5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#TY- '145D:EJ-VNK6NE:?Y*W$T;S/+,A=8T4@?=!&22<=15;3/$\4TGV+4
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M4T;Q#:ZA<SV;11;]PC=BQRA7C*CN:]#HJ'!-W9T4\34ITW3CLSG9=)U-[CQ
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M7OM7O;N*YL1'/.\JAG?(#,2,_+UYKH[?PQ>0^$]/T_SX5O[&?[1$X),98.S
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32P31SSR-&VX!5&<8[M110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_003.jpg
<TEXT>
begin 644 ex99-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !, .8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BB@]* &
MFN6\2>,[;0Y?LL$?VB[QEESA4^I_I73RN$B=R<!02<G%>2W'@[Q'=W$ER]JK
M/*QD+><G4G/K[UR8NI5C&U)7;,:LI)>XM2[#\2M2$H,MG:O&>R;E/YY/\J[O
M1-<M-=LEN+9B".'1OO*?0UXWJ6F76DW7V:\C$<NP. &#?*>.Q]JZ'X>W+Q>)
M#",[)HVW+Z$'^G]:X</BJJJJ%1_>84JT^;ED>LT445[)VA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )33@@BN1\9^*I-'5
M+*R(%U(NYG/_ "S7I^=<_P""9YM7UVY349&NXVMFRDYWK]Y>QXKEEBH*JJ2U
M;,G52GR]2Q\1_'EGI>DW.EV%PDVHW"&-_+.?)4\$D] ?0=:L_#SQS9ZYI5MI
M]W,D>J0(L91VP9@!@.OJ3CD=CFN<^(OPVLH-,FUO1(!;M -\]L@RI3NRC^$C
MJ0."/?JWPAX$T;2- C\1>*RF'59$BF)\N(,?E+ ?>8Y'7UKV.3#NAH]?QN<_
M-55;7;\+%OX@!G\4@ ')@08 SW-=#X$\-SZ<'U&^C,<\J[$C;JBYR<_C5VP\
M6>#9;B.*SU+3DEP%3HA^@) _(5U&01G(((]:\98+DK.K/=[:&T*<>;GO<?17
M-7'CSPQ9W,EK<:Q;I/$YCD0YRK X(Z>M;&G:I8:O;_:-/O(;F+INB<,!]<=*
M['&25VM#53BW9,N_A12%@JDL0 .237-7'C_PM;7)MY-;MO,!P=I+ 'T) P/Q
MH492^%7&Y);LZ:@XJM:7EM?VR7-I<1SPN,K)$X93]#67?^,/#VF7LEG>ZK;0
M7$1 >-WP5R 1_,4*,F[):@Y)*]S=HYKFAX_\*DX&N69)]'KH@0.<_P"%#BX_
M$K"4HRV8^E-95CXBTC4=0EL+._@FNX-WF1(WS+M.#^1.*U#TI--;C33V 454
MOM0M--MFN+VZBMX5ZR2N%7\S6"GQ#\)O-Y0UNV!!QE\JO_?1&/UIJ$I;*XG.
M*W9U-%1I(DT:R(X=&&593D$>H(K!N/&_AJTN);>XUFU2:)BDB,^"K X(_,4*
M,F[) Y)*[9T)^E**SM*UK3=;ADFTV\BNHXVV,T9R >N/UJ'4_$NC:-=1V^HZ
MC!;2R+N5)&P2,XS^AHY97M;4.96O?0V**C#+MW9& ,YS5/2M9T[6X'N--NXK
MJ)7V,\9R V <'\"/SI68[HT*0UGW^M:;IEU:V][>10373;8$<X,AR!@?BPJ^
M#D9HUM<+J]A>U%9.K>)-&T1@NI:E;V[D9"._S'WVCFC1_$>CZ[O&F7\-RT8!
M=8SRN?4&GRRM>V@N:-[7U->BBBD4>/>/$D7Q7<,^=K(A3Z;<?S!K.T/6YM!O
M7N8(XY':,QE9,^H/;Z5Z?XG\,0Z_;JR.(KN+_5R$=?8^WOVKSY_!&OQR^6+,
M.,XWK(F#^9!_,5X>(P]:G5<Z:O<X:M.<9\T34'CS4-3Q8-86SK<_N2!NYW<>
MOO6O\5 J_#F^50%4-",=L;UI?"O@IM+N5OM0=&N1]R).50GOD]31\5O^2>7_
M /OQ?^C%KU\M5;GBZKZ[&C4U2DY]CE]6T#P['\(K2_N+.VM[XV$3QS(H61Y2
MHXR.6R3S[<UV?PXENYO 6E/>%S)L8*7ZF/<VS_QW'Z5S'A3X9>'[S1]*U2]-
MS=2S6\<QAED'E@E<G@ 9_$UZ='&D40CC 6- %51P !VKNQ%1<K@G?5Z]O0=&
M#3Y[6T^\\:\*PZ!+XR\7C7UTYD%T_E?;"N!^\?.W=[8Z5:^&L,7_  GVO2Z+
MO.A!"B,,["VX%<?^/X[X^M<Y'X3;Q1K7C/[-DWMG=M);CL_[R3*GW.!CZ5Z5
M\-O$=IK&A"S2&*TOK+Y)[:.,("?[P ]>_H<^U=.(ERQDUK=)6[=;F%%7DKZ;
MZ]]=C-^*VJ7;C2?#=A(8WU679*RG^'<J@?0EN?I6[9_#OPO;:8+)]*MYSC#S
M2KF1CW.[J/PKF/BU#<6&IZ!XCAC+I93@2[>V&#+^>&%=K;>,/#UQIHOUU:S2
M';EM\R@I[$9R#[5S/G5&#AYWMWZ&ZY75ES]M/0X+P2LOA3XF:GX56:1[&1#)
M"KMG!PK _7:2#CKC)KL/%GAC1+K2-7U*;3+62\-K*_G,@+;@G!S[8%<GX+9O
M%7Q.U3Q3'$R:?"OEPNXQN;:%'X[02?3(%>A^)L#PIK _Z<IO_0#3K2:JQMOI
M?\":2O3=_.QP'PP\,:'JG@Z"[OM+M;B?SI!YLD8+<'UKN_%&KKH/AG4-1XWP
MQ'RP>[GA1^9%<W\(O^1!A_Z[R_\ H59/Q;N[G4;C2?"VG)YMU=2><T8(&0 0
MH)_[Z/\ P&FX^TQ%F]+C3Y*%T<;HMM=>#=1\+^)+AV\G4MXFW=D9L9/U5E;\
M#7T$,')%>->*[3QMJWA=K.^\/6,%E9@2AX)E+1JB]OG/;(X%>@?#_6QKO@RQ
MN7;,\2>1-Z[DX_48/XT\2G."J.W5.WX"H-1FX+M_PYPUE:?\+*\?ZC)J4CMH
M^E.8XK=6P&.2!T[-M))]@*[BY\#>%&M#"^B62H!C<$VM_P!]=?UK@O"VI0^!
M/'^M:5J[>1;7LF^*=N$ #,4)/8$,1[$8K;^*NK:;=^"'CMM0M9I))HF58YE8
ML,GD#-54C/VL8QTB[6MZ?YDP<53DWOJ>BQ(D<*)& (U "@=A7C'AT^&!XV\6
M#Q)]@V_:V\G[7C&?,?=MS^%>L>'?^17TG_KRA_\ 0!7E?A>U\/W7C?Q<->2P
M8+>-Y0NW4#/F29VY]L5GAO=C43;VZ;[FE9WE!KO^AZ;X<&@?8I6\/"S%J93Y
MAM0-N_ ]/;%>:_%32Y=9\>:3I\) FFLF$>>A8%R!^)%>G:#;Z):VDD>A"S%J
M9-SBU8%=V .Q] *XGQ7_ ,EE\+_]<?ZR48:5JSDK[/??85:-Z5G;IL3_  P\
M4OJVB2Z/?$KJ&GH5(<_,T?0?BOW3^%1?!+_D5+[_ *_F_P#0$K)\>:;/X.\7
MVGB_3%/V>:3;=(.FX\-^#C]1[UK?!/'_  BM\<?\OS=_]A*UG%>QG4AL^7[^
MI,)/VJ@^E_NT(?BC_P C9X-_Z^O_ &I%7H&OZE_8_A_4-1 4FW@>0!NA8#@?
MGBO/_BE_R-G@W_KZ_P#:D5=SXKTZ35O"FJ6,(S+-;N(U]6QD#\Q64K<M*^W_
M  2U\52WE^1Y]\.O"%EX@TZ7Q+XAC_M&ZO)7V"<[E"@X)(Z$Y!]L8KT32_#N
MD:-<32Z980VSS;1)Y8QN )(X_$UP/PL\6Z9;>'QH>H745G=VDKA1.VS>I8MU
M/&021CVKT2RUC3=0N'AL;^VN)(P"ZPRJY4'IT-+$.KSM.]NG:W0='D<4UO\
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M*LK7/VH.'Y5_;V]JV<;1CKBGXI*%&*>B!*VQDG0-/DO+FZF@6>6X(W&90VW
MQA>.*LZ;I\.EV,5G SM%&"%\QLG!/KZ5>I*%&*=T@Y5>Y2NM-@N[RSNI-_F6
MK,T>#CEA@YJ[CBBEJK6U&9NK:3!JT,23/+'Y4@E5HGVD,,X.?QJ:QM/L-JL
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&%%%6,__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
